Drug Profile
Research programme: recombinant Fc multimer proteins - Momenta Pharmaceuticals
Alternative Names: Anti-CTLA-4 Fc multimer - Momenta Pharmaceuticals; Anti-CTLA-4 multivalent IgG1 Fc agent - Momenta Phamaceuticals; Anti-CTLA-4 SIFbody - Momenta PhamaceuticalsLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Momenta Pharmaceuticals
- Developer CSL Behring; Momenta Pharmaceuticals
- Class Antineoplastics; Immunoglobulin Fc fragments; Recombinant proteins
- Mechanism of Action Fc receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in USA (IV, Infusion)
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson
- 28 Feb 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (IV, Infusion)